SI2373681T1 - Farmacevtski sestavki albiglutida - Google Patents
Farmacevtski sestavki albiglutidaInfo
- Publication number
- SI2373681T1 SI2373681T1 SI200931639A SI200931639A SI2373681T1 SI 2373681 T1 SI2373681 T1 SI 2373681T1 SI 200931639 A SI200931639 A SI 200931639A SI 200931639 A SI200931639 A SI 200931639A SI 2373681 T1 SI2373681 T1 SI 2373681T1
- Authority
- SI
- Slovenia
- Prior art keywords
- albiglutide
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12122908P | 2008-12-10 | 2008-12-10 | |
US15090909P | 2009-02-09 | 2009-02-09 | |
US16399509P | 2009-03-27 | 2009-03-27 | |
US23872309P | 2009-09-01 | 2009-09-01 | |
PCT/US2009/067469 WO2010068735A1 (en) | 2008-12-10 | 2009-12-10 | Pharmaceutical compositions |
EP09832522.8A EP2373681B1 (en) | 2008-12-10 | 2009-12-10 | Pharmaceutical compositions of albiglutide |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2373681T1 true SI2373681T1 (sl) | 2017-05-31 |
Family
ID=42243062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931639A SI2373681T1 (sl) | 2008-12-10 | 2009-12-10 | Farmacevtski sestavki albiglutida |
Country Status (13)
Country | Link |
---|---|
US (3) | US8748377B2 (sl) |
EP (1) | EP2373681B1 (sl) |
JP (1) | JP2012511586A (sl) |
CY (1) | CY1118731T1 (sl) |
DK (1) | DK2373681T3 (sl) |
ES (1) | ES2620610T3 (sl) |
HR (1) | HRP20170478T1 (sl) |
HU (1) | HUE031900T2 (sl) |
LT (1) | LT2373681T (sl) |
PL (1) | PL2373681T3 (sl) |
PT (1) | PT2373681T (sl) |
SI (1) | SI2373681T1 (sl) |
WO (1) | WO2010068735A1 (sl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
JP2013525491A (ja) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 心血管障害を治療または予防し心血管保護を提供する方法 |
US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
BR112014032938A2 (pt) | 2012-07-01 | 2017-08-01 | Novo Nordisk As | uso de peptídeos de glp-1 de longa ação |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR094180A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Derivados de exendina-4 |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
AU2014272500B2 (en) | 2013-05-28 | 2018-03-08 | Scohia Pharma, Inc. | Peptide compound |
US20140378374A1 (en) * | 2013-06-21 | 2014-12-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treatment |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR100942A1 (es) * | 2014-06-25 | 2016-11-09 | Glaxosmithkline Llc | Composiciones y método para el control glucémico que comprenden albiglutida |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
US11045522B2 (en) | 2017-09-22 | 2021-06-29 | Regeneren Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
KR20200069316A (ko) | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011457A1 (en) * | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
CA2501421A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
MXPA02011339A (es) | 2000-05-19 | 2003-04-25 | Amylin Pharmaceuticals Inc | Tratamiento del sindrome coronario agudo con glp-1. |
SI1324776T2 (sl) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Koncentrirane proteinske formulacije z zmanjšano viskoznostjo |
NZ519752A (en) | 2000-10-20 | 2005-04-29 | Amylin Pharmaceuticals Inc | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
UA81897C2 (uk) | 2000-12-07 | 2008-02-25 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-1-подібний білок та його застосування для для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння та/або інсулінонезалежний діабет |
WO2002047716A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
RU2353625C2 (ru) | 2001-10-18 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний |
EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2003200839B2 (en) | 2002-01-08 | 2008-12-11 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
EP1494704A1 (en) | 2002-04-04 | 2005-01-12 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
JP2006514035A (ja) | 2002-12-17 | 2006-04-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 心不整脈の予防および治療 |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
WO2005120492A1 (en) | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
MX2007007602A (es) | 2004-12-22 | 2007-12-07 | Johnson & Johnson | Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. |
AU2005323063B2 (en) | 2004-12-24 | 2011-01-27 | Amylin Pharmaceuticals, Llc | Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis |
EP1871403B1 (en) | 2005-03-31 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention and treatment of eating disorders |
EP1909824B1 (en) * | 2005-04-08 | 2011-05-18 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
DK1888103T3 (da) | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering |
DK1965823T3 (en) | 2005-11-04 | 2016-08-22 | Glaxosmithkline Llc Corp Service Company | Methods of administering hypoglycemics |
WO2007139941A2 (en) | 2006-05-26 | 2007-12-06 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
BRPI0714334A2 (pt) | 2006-07-18 | 2013-05-14 | Centocor Inc | mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos |
EP2068910A2 (en) | 2006-08-04 | 2009-06-17 | Amylin Pharmaceuticals, Inc. | Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
CL2007002634A1 (es) * | 2006-09-13 | 2008-05-16 | Smithkline Beecham Corp | Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. |
EP2163243A1 (en) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof |
PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
-
2009
- 2009-12-10 PT PT98325228T patent/PT2373681T/pt unknown
- 2009-12-10 EP EP09832522.8A patent/EP2373681B1/en active Active
- 2009-12-10 JP JP2011540882A patent/JP2012511586A/ja active Pending
- 2009-12-10 LT LTEP09832522.8T patent/LT2373681T/lt unknown
- 2009-12-10 DK DK09832522.8T patent/DK2373681T3/en active
- 2009-12-10 SI SI200931639A patent/SI2373681T1/sl unknown
- 2009-12-10 HU HUE09832522A patent/HUE031900T2/en unknown
- 2009-12-10 PL PL09832522T patent/PL2373681T3/pl unknown
- 2009-12-10 WO PCT/US2009/067469 patent/WO2010068735A1/en active Application Filing
- 2009-12-10 US US13/133,976 patent/US8748377B2/en not_active Expired - Fee Related
- 2009-12-10 ES ES09832522.8T patent/ES2620610T3/es active Active
-
2014
- 2014-04-25 US US14/261,641 patent/US20140228284A1/en not_active Abandoned
- 2014-04-25 US US14/261,602 patent/US20140228288A1/en not_active Abandoned
-
2017
- 2017-03-16 CY CY20171100337T patent/CY1118731T1/el unknown
- 2017-03-21 HR HRP20170478TT patent/HRP20170478T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT2373681T (pt) | 2017-04-11 |
CY1118731T1 (el) | 2017-07-12 |
WO2010068735A1 (en) | 2010-06-17 |
LT2373681T (lt) | 2017-04-10 |
US8748377B2 (en) | 2014-06-10 |
US20110301080A1 (en) | 2011-12-08 |
HRP20170478T1 (hr) | 2017-05-19 |
ES2620610T3 (es) | 2017-06-29 |
PL2373681T3 (pl) | 2017-07-31 |
US20140228288A1 (en) | 2014-08-14 |
JP2012511586A (ja) | 2012-05-24 |
US20140228284A1 (en) | 2014-08-14 |
EP2373681A1 (en) | 2011-10-12 |
EP2373681B1 (en) | 2017-01-18 |
HUE031900T2 (en) | 2017-08-28 |
DK2373681T3 (en) | 2017-04-24 |
EP2373681A4 (en) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2373681T3 (pl) | Kompozycje farmaceutyczne albiglutydu | |
EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0814695D0 (en) | Pharmaceutical compositions | |
IL228817A0 (en) | Pharmaceutical compounds | |
PL2323623T3 (pl) | Kompozycje farmaceutyczne | |
EP2271347A4 (en) | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | |
EP2341773A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN | |
ZA201102715B (en) | Solid pharmaceutical composition | |
IL208387A0 (en) | Pharmaceutical composition | |
ZA201104670B (en) | Pharmaceutical composition comprising aleglitazar | |
ZA201100871B (en) | Solid pharmaceutical composition | |
EP2296687A4 (en) | PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES | |
ZA201006224B (en) | Pharmaceutical composition | |
EP2327406A4 (en) | STABILIZED PHARMACEUTICAL COMPOSITION | |
ZA201101053B (en) | Pharmaceutical compositions of samatotrophic hormones | |
IL206487A0 (en) | Pharmaceutical compositions | |
GB2464200B (en) | Pharmaceutical composition | |
GB0817969D0 (en) | Pharmaceutical composition | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
GB0804485D0 (en) | Novel pharmaceutical compositions | |
GB0805807D0 (en) | Novel pharmaceutical compositions | |
GB0802024D0 (en) | Pharmaceutical compositions | |
GB0806156D0 (en) | Pharmaceutical compositions | |
GB0806283D0 (en) | Pharmaceutical compositions |